Track the Tharimmune, Inc. stock price and the full directors' dealings record of the company, a publicly traded company based in United States. Shares are listed on US US, under the authority of SEC (Form 4). Market capitalisation: €1.8bn. The latest transaction was reported on 16 May 2025 (Acquisition). Among the most active insiders: MILBY RANDY. The full history is free.
8
Insider Decl.
n/a
Thresholds
€62,641
8 ops.
Buy Volume
n/a
n/a
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Tharimmune, Inc. Strong Buy (bullish), based on 10 analysts. Average price target: US$57.10.
43Σ signal
Buys €62,641n/a Sells
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.